Veracyte PE Ratio 2012-2024 | VCYT
Current and historical p/e ratio for Veracyte (VCYT) from 2012 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Veracyte PE ratio as of May 01, 2025 is 41.85.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Veracyte PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-05-01 | 29.71 | 99.03 | |
| 2024-12-31 | 39.60 | $0.30 | 132.00 |
| 2024-09-30 | 34.04 | $-0.15 | 0.00 |
| 2024-06-30 | 21.67 | $-0.75 | 0.00 |
| 2024-03-31 | 22.16 | $-0.94 | 0.00 |
| 2023-12-31 | 27.51 | $-1.03 | 0.00 |
| 2023-09-30 | 22.33 | $-0.69 | 0.00 |
| 2023-06-30 | 25.47 | $-0.40 | 0.00 |
| 2023-03-31 | 22.30 | $-0.41 | 0.00 |
| 2022-12-31 | 23.73 | $-0.50 | 0.00 |
| 2022-09-30 | 16.60 | $-0.60 | 0.00 |
| 2022-06-30 | 19.90 | $-0.68 | 0.00 |
| 2022-03-31 | 27.57 | $-0.68 | 0.00 |
| 2021-12-31 | 41.20 | $-1.14 | 0.00 |
| 2021-09-30 | 46.45 | $-1.13 | 0.00 |
| 2021-06-30 | 39.98 | $-1.01 | 0.00 |
| 2021-03-31 | 53.75 | $-1.10 | 0.00 |
| 2020-12-31 | 48.94 | $-0.68 | 0.00 |
| 2020-09-30 | 32.49 | $-0.69 | 0.00 |
| 2020-06-30 | 25.90 | $-0.63 | 0.00 |
| 2020-03-31 | 24.31 | $-0.46 | 0.00 |
| 2019-12-31 | 27.92 | $-0.27 | 0.00 |
| 2019-09-30 | 24.00 | $-0.20 | 0.00 |
| 2019-06-30 | 28.51 | $-0.30 | 0.00 |
| 2019-03-31 | 25.02 | $-0.43 | 0.00 |
| 2018-12-31 | 12.58 | $-0.65 | 0.00 |
| 2018-09-30 | 9.55 | $-0.81 | 0.00 |
| 2018-06-30 | 9.34 | $-0.90 | 0.00 |
| 2018-03-31 | 5.56 | $-0.94 | 0.00 |
| 2017-12-31 | 6.53 | $-0.91 | 0.00 |
| 2017-09-30 | 8.77 | $-0.81 | 0.00 |
| 2017-06-30 | 8.33 | $-0.80 | 0.00 |
| 2017-03-31 | 9.18 | $-0.98 | 0.00 |
| 2016-12-31 | 7.74 | $-1.10 | 0.00 |
| 2016-09-30 | 7.61 | $-1.25 | 0.00 |
| 2016-06-30 | 5.03 | $-1.37 | 0.00 |
| 2016-03-31 | 5.40 | $-1.32 | 0.00 |
| 2015-12-31 | 7.20 | $-1.30 | 0.00 |
| 2015-09-30 | 4.69 | $-1.37 | 0.00 |
| 2015-06-30 | 11.14 | $-1.42 | 0.00 |
| 2015-03-31 | 7.28 | $-1.38 | 0.00 |
| 2014-12-31 | 9.66 | $-1.36 | 0.00 |
| 2014-09-30 | 9.75 | $-1.42 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $2.327B | $0.446B |
| Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. | |||